For example, melanoma secretomes activate NF‐κB in tumor‐associated B cells (TABs), which in turn induces the differentiation of TABs into tumor‐induced plasmablast‐like‐enriched B cells (TIPBs).[32] The inhibitory ligands on the surface of TIPB, Galectin‐9, and TNFRSF14 are upregulated, which bind to TIM‐3 and BTLA on the surface of T cells. Here, NFKB1 is linked to neoplasm.